Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15082631 | 0.83 | LMNA (0.35) | CYP3A4CYP1A2CYP2D6NFKB1PNMT | |
| SCHEMBL12985509 | 0.82 | CYP3A4 (0.38) | CYP3A4CYP1A2CYP2D6NFKB1PNMT | |
| SCHEMBL11709410 | 0.81 | LMNA (0.34) | CYP3A4CYP1A2CYP2D6NFKB1PNMT | |
| SCHEMBL14373062 | 0.80 | CYP3A4 (0.41) | CYP3A4CYP1A2CYP2D6NFKB1PNMT | |
| SCHEMBL25596329 | 0.79 | LMNA (0.36) | CYP3A4CYP1A2LMNAALDH1A1TP53 | |
| SCHEMBL12678217 | 0.77 | LMNA (0.32) | LMNATP53HTTGABRA1GABRB1 | |
| SCHEMBL1292825 | 0.76 | GABRA1 (0.41) | CYP3A4CYP1A2LMNAGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL28139693 | 0.74 | LMNA (0.41) | CYP3A4CYP1A2CYP2D6NFKB1PNMT | |
| SCHEMBL18885910 | 0.74 | LMNA (0.36) | CYP3A4CYP1A2LMNATP53HTT | |
| SCHEMBL21567158 | 0.74 | CYP3A4 (0.38) | CYP3A4CYP1A2CYP2D6NFKB1PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | OREGON STATE UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-10786494-B2 | CCR6 compounds | CHEMOCENTRYX, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| WO-2020185695-A1 | ANALOGUES AND DERIVATIVES OF CEPHALOTAXINE AND METHODS FOR MAKING AND USING THE COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20190167659-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20180092902-A1 | CCR6 COMPOUNDS | CHEMOCENTRYX, INC. | 2018-04-05 | — | — | US | disclosed |
| US-9795599-B2 | CCR6 compounds | CHEMOCENTRYX, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9795599-B2 | CCR6 compounds | CHEMOCENTRYX, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160296508-A1 | CCR6 COMPUNDS | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9458155-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-9434747-B2 | Methods of treating diabetes | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-8907097-B2 | Pyrido[4,3-b]indoles containing rigid moieties | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140303144-A1 | COMPOUNDS AND METHODS OF TREATING HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140228353-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130190293-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-07-25 | — | — | US | disclosed |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | MEDIVATION TECHNOLOGIES, INC. | 2010-08-26 | — | — | US | disclosed |
| EP-0322869-B1 | PROCESS FOR SEPARATING DICHLOROCUMENE ISOMER | TORAY INDUSTRIES, INC. (JP) | 1992-09-09 | — | — | EP | disclosed |
| US-4922039-A | Process for separating dichlorocumene isomer | TORAY INDUSTRIES (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0322869-A2 | Process for separating dichlorocumene isomer | TORAY INDUSTRIES, INC. (JP) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190293-A1 | PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | CYP3A4 284/4885CYP1A2 761/4885CYP2D6 256/4885 |
| US-20140296209-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION | ADRB2, ADRA2B, ADRB1 | CYP3A4 736/4885CYP1A2 401/4885CYP2D6 1375/4885 |
| US-20160296508-A1 | CCR6 COMPUNDS | CCR6, CCR1, CCR4 | CYP3A4 2933/4885CYP1A2 2229/4885CYP2D6 161/4885 |
| US-20140303144-A1 | COMPOUNDS AND METHODS OF TREATING HYPERTENSION | ADRB2, ADRA2B, ADRA2C | CYP3A4 712/4885CYP1A2 343/4885CYP2D6 1120/4885 |
| US-20100216814-A1 | PYRIDO[4,3-B]INDOLES CONTAINING RIGID MOIETIES | HTR3B, HTR3D, HTR3A | CYP3A4 662/4885CYP1A2 842/4885CYP2D6 336/4885 |
| US-20190167659-A1 | CCR6 COMPOUNDS | CCR6, CCR1, CCR4 | CYP3A4 1659/4885CYP1A2 1609/4885CYP2D6 68/4885 |
| US-20140228353-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2B, ADRA2C | CYP3A4 903/4885CYP1A2 247/4885CYP2D6 1141/4885 |
| US-20180092902-A1 | CCR6 COMPOUNDS | CCR6, CCR1, CCR4 | CYP3A4 1659/4885CYP1A2 1609/4885CYP2D6 68/4885 |
| US-10786494-B2 | CCR6 compounds | CCR6, CCR1, CCR4 | CYP3A4 1659/4885CYP1A2 1609/4885CYP2D6 68/4885 |
| US-20140155384-A1 | COMPOUNDS AND METHODS OF TREATING DIABETES | ADRB2, ADRA2C, ADRA2B | CYP3A4 842/4885CYP1A2 300/4885CYP2D6 1199/4885 |
| US-11708377-B2 | Analogues and derivatives of cephalotaxine and methods for making and using the compounds | SLC6A2, NAPRT, SLC6A3 | CYP3A4 2094/4885CYP1A2 255/4885CYP2D6 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.